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for the American Society of Blood and Marrow Transplantation Committee on EducationAdvances in hematopoietic progenitor cell transplantation (HCT) have led to an increasing number of trans-
plantations and a concomitant requirement for physicians skilled in transplantation care. Guidelines for train-
ing HCT physicians were published in 2001; however, the past decade has seen a rapid expansion of the
medical knowledge and skill set that these physicians need to deliver the highest quality of care. Recognizing
the importance of education for transplantation programs, the American Society of Blood and Marrow
Transplantation established a Committee on Education in 2010. The Committee’s updated guidelines pre-
sented here provide an extensive and detailed framework for use by HCTeducators and directors in devel-
oping HCT training programs and evaluating and mentoring their trainees.
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Hematopoietic progenitor cell transplantation
(HCT) offers the best chance for cure and/or long-
term survival for a broad range of diseases, including
hematologic malignancies, bone marrow failure states,
immunodeficiencies, and inherited metabolic disor-
ders. From the pioneering clinical efforts of Thomas
and others and subsequent efforts culminating in the
first successful HLA-matched HCT in 1967 [1],
a stream of scientific advances has facilitated clinical
breakthroughs in autologous and allogeneic HCT.
This has led to a dramatic increase in transplantation
volume with more than 50,000 HCTs performed
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6/j.bbmt.2012.04.007plantations were performed in North America, includ-
ing approximately 10,300 autologousHCTs and 6,700
allogeneic HCTs [2]. With increasing numbers of
patients medically eligible for HCT, this growth is ex-
pected to continue, with the National Marrow Donor
Program (NMDP) estimating that we will witness an
additional 30%-50% increase in autologous and allo-
geneic HCT volume and an expected doubling of
unrelated and alternative donorHCTvolume, by 2015.REVISION OF TRAINING GUIDELINES
A primary objective of the American Society for
Blood andMarrowTransplantation (ASBMT) is to en-
sure the highest quality of medical practice in patients
undergoing HCT. Given the continued increases in
the number of patients requiringHCT, transplantation
centers will require a parallel increase in the number of
physicians skilled in HCT care. On 2 previous occa-
sions, the ASBMT has developed and published brief
guidelines outlining cognitive and procedural skills
necessary for providing optimal care for HCT recipi-
ents [3,4]. In response to the growing demand for
transplantation physicians and the progressive
complexity of HCT care, an increasing number of
centers have developed dedicated educational
programs to train adult and pediatric HCT
physicians. In recognition of the importance of
education in ensuring the future success of HCT
programs, the ASBMT established a Committee on
Education in 2010. One of the first priorities of this
Biol Blood Marrow Transplant 18:1322-1328, 2012 1323Guidelines for Training in HCTnewCommitteewas to revisit and expand guidelines for
HCT training programs. AlthoughHCT training does
not currently lead to certification by the Accreditation
Committee on Graduate Medical Education
(ACGME) [5], the Committee recognized the impor-
tance of aligning recommendations to the 6 areas of
Core Competencies defined by the ACGME, given
the widespread adoption of ACGME core competency
frameworks for the establishment and review of educa-
tional training programs at academic medical centers.GENERAL ASBMT REQUIREMENTS FOR
TRAINING PROGRAMS
It is the ASBMT’s position that all physicians per-
forming peripheral blood, cord blood, and bone mar-
row transplantations must be licensed to practice
medicine and should be board certified or eligible
and have the requisite training and experience in he-
matology, medical oncology, immunology, and/or pe-
diatric hematology/oncology. In addition, physicians
performing HCT must receive specific training in
the cognitive and procedural areas listed below. This
training should be conducted in a program compliant
with the ASBMT Guidelines for Clinical Centers
and accredited by the Foundation for the Accredita-
tion of Cell Therapy (FACT) or an equivalent accred-
itation program. The ASBMT recommends at least 12
months of HCT-specific training for a physician plan-
ning a career in transplantation, along with additional
clinical mentoring by an experienced transplantation
physician as part of the career development of a junior
faculty member.CURRICULUM GOALS
The training curriculum should provide a system-
atic framework for advanced training in the field of
HCT. Academic training programs should ensure
the highest quality of medical practice in HCT, while
providing a rigorous educational environment for sci-
entific and clinical training. The training should in-
clude clinical excellence in the nontransplantation
management of relevant diseases as well.MENTORING
In addition to the curriculum, a key component of
any training program is effective mentoring. Each
trainee should have at least one primary mentor
throughout the training period.However, it is being in-
creasingly recognized that one mentor is unlikely to be
able to provide guidance in all areas, and that a team of
mentors is optimal whenever possible. The mentor(s)
shouldmeet on a frequent basiswith the trainee tomon-
itor progress in each of the core competencies and toaddress issues related to balancing a demanding career
with non–work-related responsibilities.EDUCATIONAL GOALS
By the completion of HCT training, trainees
should have achieved the following goals:
 Develop a sound understanding of underlying path-
ophysiological principles of HCT, including those
of hematopoiesis and immunology.
 Become clinically competent in the care of adult
and/or pediatric patients with nonmalignant and
malignant disorders treated by HCT.
 Achieve competency in the procedural and technical
skills required in the evaluation and care of HCT
recipients.SPECIFIC EDUCATIONAL OBJECTIVES FOR
HCT TRAINING BYACGME CORE
COMPETENCY
I. Medical Knowledge
Trainees must demonstrate knowledge about es-
tablished and evolving biomedical, clinical, and
cognate ([eg, epidemiologic and social behavioral] sci-
ences) and the application of this knowledge to patient
care. They are expected to demonstrate an investiga-
tory and analytical thinking approach to clinical situa-
tions and to know and apply the basic and clinically
supportive sciences appropriate to transplantation.
Trainees should have an appreciation of the history
and evolution of HCT as a therapeutic modality, to
understand the translation of basic science discoveries
into clinical practice and the importance of carefully
designed clinical trials that further our understanding
of the application of HCT as a therapeutic modality
for both malignant and nonmalignant disorders.
Trainees should understand the underlying patho-
physiological principles of HCT, including hemato-
poiesis and immunology, as well as the indications,
evaluation, management, and outcomes for the dis-
eases treated with HCT, and be able to compare
non-HCT therapeutic options and outcomes with
those of HCT. They should also know the indications
for autologous and allogeneic-related and unrelated
HCT, along with the differences in patient manage-
ment, complications, and outcomes by donor source
and conditioning regimen, and be able to appropri-
ately evaluate a potential HCT recipient and donor.
The trainee must be able to counsel patients about
the early and late complications of HCT, including
monitoring, diagnosis, and management, and imple-
ment an appropriate plan for post-HCT care. Finally,
an integral part of anHCT physician’s knowledge base
includes the ordering and interpretation of clinical lab-
oratory tests and procedures and the appropriate use of
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immunotherapy for optimal care of HCT recipients.
The HCT trainee should meet all the following
specific objectives related to medical knowledge:
A. Pathophysiological principles
1. Hematopoiesis Types of hematopoietic stem cells, including
pleuripotent versus committed progenitors
 Basics of hematopoietic differentiation
 Engraftment of transplanted hematopoietic
stem cells
2. Basic immunology
 Major histocompatibility complex function,
tissue distribution, and genetics
 Lymphoid development
 T cell, B cell, and natural killer cell biology
and functions
 Immunologic memory
 Antigen presentation, antigen-presenting
cells, and antigen receptors
 Principles of innate immunity
 Natural and induced T regulatory cells
 Immune reconstitution posttransplantation
 Data supporting/not supporting graft-versus-
leukemia/lymphoma effect in allogeneic HCT
B. Indications for HCT (adult and pediatric)
1. Acute and chronic leukemias
2. Myeloproliferative and myelodysplastic syn-
dromes
3. Plasma cell dyscrasias
4. Lymphoproliferative diseases
5. Paroxysmal nocturnal hemoglobinuria
6. Aplastic anemia and other marrow failure states
7. Solid tumors
8. Autoimmune disorders
9. Hemoglobinopathies
10. Pediatric metabolic disorders
11. Pediatric primary immune deficiencies, includ-
ing severe combined immunodeficiency and
non–severe combined immunodeficiency forms
C. Pre-HCT evaluation of recipients and donors
1. Recipient disease staging
2. Evaluation of recipient comorbidities
3. Donor selection, evaluation of suitability for do-
nation, and ethical issues pertaining to donor
choice
4. Stem cell mobilization and collection from pe-
ripheral blood and bone marrow
5. Selection and understanding of conditioning
regimens
6. Planning for posttransplantation therapy if indi-
cated (eg, radiation therapy, maintenance ther-
apy).
7. Assessment of a patient’s caregiver situation and
availability of adequate resourcesD. Pathophysiology, diagnosis, evaluation, and man-
agement of early HCT issues
1. Management of hematopoietic cell infusion
toxicities and guidelines for infusion of ABO-
incompatible cell components
2. Principles of infection control (eg, environment,
diet, handwashing, masks)
3. Fungal, viral, and bacterial prophylaxis
4. Short-term complications and an understanding
of the relative frequencies of each in terms of dif-
ferent conditioning regimens and immunosup-
pressive therapies, including:
 Mucositis (preventative strategies, evaluation,
scoring, and therapy)
 Infections (evaluation, diagnosis and therapy
of all fungal, viral [including cytomegalovirus,
human herpes virus 6, adenovirus, and respira-
tory syncytial virus]) and bacterial infections
 Hemorrhagic cystitis
 Veno-occlusive disease (liver and pulmonary)
 Interstitial and noninterstitial pneumonias
 Diffuse alveolar hemorrhage
 Hemolysis
 Organ failure
 Alloimmunization and transfusion strategies
 Engraftment (neutrophils, red cells, and plate-
lets) and chimerism
 Minimal residual disease
 Early graft failure (diagnosis and management
options)
 Acute graft-versus-host disease (GVHD) (in-
cluding alloimmunity, role of CD4 and CD8
cells, and methods for prevention of disease
and treatment)
 Common side effects and drug interactions
from standard transplantation therapiesE. Pathophysiology, diagnosis, evaluation, and man-
agement of late HCT issues
1. Chronic GVHD
2. Posttransplantation immunodeficiencies
3. Posttransplantation autoimmune cytopenias
4. Late graft failure
5. Relapse (including management with donor
lymphocyte infusions)
6. Second cancers, including posttransplantation
lymphoproliferative disease
7. Late toxicities of all organ systems
8. Long-term follow-up guidelines and immuniza-
tion schedules
9. Psychosocial issues, including those of care-
givers
10. End-of-life issues
F. Methods and interpretations of clinical laboratory
testing
1. Blood smears
2. Cell counting technology
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4. Red cell autoantibody and alloantibody testing
5. Red cell phenotyping and cross-matching
6. Basic cell viability assays
7. CD341 cell evaluation
8. HLA typing
9. Donor search using the NMDP Traxis system
10. Apheresis techniques
11. Testing methods for chimerism
12. Polymerase chain reaction techniques for mini-
mal residual disease
13. Infectious disease testing for pathogens, includ-
ing cytomegalovirus, respiratory syncytial virus,
adenovirus, Epstein-Barr virus, and fungal and
bacterial pathogens
14. Interpretation of pulmonary function test results
G. Indications for, appropriate use of, and interpreta-
tion of results of procedures related to HCT
1. Bone marrow biopsy and aspiration
2. Immunophenotyping, cytogenetics, and molec-
ular studies of blood and marrow
3. Lumbar puncture and intraventricular access
with instillation of chemotherapy by both routes
4. Management of indwelling catheters, including
infections and thrombosis
5. Accurate ordering of chemotherapy and anti-
emetics
6. Hematopoietic cell apheresis for allogeneic or
autologous HCT
7. Cryopreservation of cellular products
8. Thawing and administration of cellular products
H. Use of medications, blood product support, and
chemotherapies pertaining to the practice of HCT
1. Immunomodulating drugs for prophylaxis and
therapy
2. Monoclonal antibodies (eg, rituximab) in mobi-
lization, preparative regimens, and posttrans-
plantation maintenance
3. Chemotherapy andmodifications by organ func-
tion
4. All types of blood products
5. Supportive care and medications for pain and
symptom management
I. Knowledge pertaining to the practice of HCT
1. Principles of safe and effective blood banking
2. Cryopreservation, storage, and manipulation of
hematopoietic stem cells and other cellular
products used for HCT
3. Requirements for accreditation of a hematopoi-
etic stem cell laboratory from:
 American Association of Blood Banks
 FACT
 Food and Drug Administration (FDA)II. Patient Care
Although the provision of patient care forms the
fundamental basis for clinical training programs, theACGME specifically suggests that clinical training
programs should teach trainees to deliver care that is
compassionate, appropriate, and effective for the treatment
of health problems and the promotion of health. HCT
is a complex subspecialty that requires practitioners to
integrate information obtained by history and physical
examination, in addition to information derived from
medical records, from referring physicians, and from
laboratory and imaging studies.
To design and implement optimal HCT clini-
cal strategies, trainees must learn to develop ther-
apeutic strategies that include clinical, laboratory,
and cellular therapy elements. HCT plans should
be devised based on a thorough understanding of
the medical literature and of statistical principles
underlying diagnostic tests and therapeutic inter-
ventions. These plans are often best derived in
conjunction with teams composed of nursing and
consultants in such areas as infectious disease, pul-
monary, gastroenterology, nephrology, cardiology,
social services, nutrition services, and occupational
and physical therapy. Given the often-significant
risk of morbidity and mortality associated with
HCT, transplantation physicians need to consider
the importance of comorbidity and to consider
quality of life in medical decision making. It is
the responsibility of the transplantation physician
to oversee development of these patient care plans
in collaboration with patients and families and to
communicate effectively and with compassion to
ensure understanding and compliance. The opti-
mum care of HCT recipients also requires strong
competency in transplantation procedures, includ-
ing diagnostic biopsies, collection of autologous
and allogeneic cells, and administration of the con-
ditioning regimen and progenitor and lymphocyte
products.
Specific objectives that should be included inHCT
training programs related to patient care include the
following:
A. Demonstrate clinical skills and the ability to gather
pertinent information.
1. Perform an effective medical interview and phys-
ical examination in both the inpatient and outpa-
tient settings.
2. Choose cost-effective laboratory and imaging
studies pertinent to the current problem.
3. Interact with laboratory personnel to gather rel-
evant information about specialized hematologic
and HCT-related testing.
4. Acquire and carefully review the patient’s re-
cords and other clinical information.
5. Manage time effectively.
B. Problem identification and information synthesis
1. Synthesize the relevant clinical and laboratory in-
formation into a prioritizeddifferential diagnosis.
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provide a coordinated and cohesive approach to
diagnosis and clinical management.
3. Generate diagnostic strategies and coordinate
laboratory and blood bank efforts to provide
effective support for HCT recipients.
4. Apply principles of diagnostic reasoning that in-
clude an appreciation of biostatistics (including
probability estimates, Bayes theorem, likelihood
ratios, and test performance characteristics).
C. Development and execution of a treatment man-
agement plan
1. Integrate patient-specific information and diag-
nostic findings into an HCT plan tailored to
the individual patient’s unique needs.
2. Understand the importance of comorbidities
that may influence the outcomes of HCT.
3. Understand and respond to common drug inter-
actions and side effects.
4. Understand the potential impact of HCT strate-
gies on quality of life.
5. Effectively and compassionately include and en-
gage the nursing staff, patient, and family in the
development and execution of the HCT plan.
6. Identify and discuss clear outcome goals for
HCT.
7. Monitor and encourage compliance.
D. Procedures
1. Provide adequate information of risks and bene-
fits of procedures to allow patients make an in-
formed decision regarding consent.
2. Provide skillful procedural services, including:
 Autologous and allogeneic hematopoietic
stem cell apheresis
 Bone marrow biopsy and aspiration
 Bone marrow harvest for transplantation
 Lumbar puncture and other intraventricular
access and administration of intrathecal che-
motherapy
 Administration of antineoplastic chemother-
apy and immunotherapy
 Administration of immunosuppressive medi-
cal and biologic therapies
 Cryopreservation of hematopoietic stem cells
 Thawing and administration of hematopoietic
progenitor cells
 Administration of therapeutic lymphocyte in-
fusions
 Skin biopsyIII. Interpersonal and Communication Skills
The ACGME states that trainees ‘‘must demon-
strate interpersonal and communication skills that re-
sult in the effective exchange of information and
collaboration with patients, their families and health
professionals [5].’’ The trainees must be capable of
communicating across socioeconomic and culturalbarriers to a range of stakeholders, including patients,
family members, all medical personnel, and the public
as needed to support the provision of medical care.
The ability to communicate is a necessary component
of being an effective leader or member of a health care
team and should also be taught and assessed in an
educational program. In addition, the learner must
be capable of communicating effectively using forms
of media comprising a medical record, including elec-
tronic medical records.
HCT team members must necessarily be compe-
tent verbal and nonverbal communicators, given the
reliance on multiple stakeholders for a successful
HCT experience. A physician must be capable of com-
municating options, risks, and benefits of complex pro-
cedures to patients and some referring physicians who
are unfamiliar with the topics but are nonetheless re-
quired to contribute to informed decision making.
Information must be effectively shared with other pro-
viders, insurers, donor search specialists, coordinators,
and data managers. At the time of transition to outpa-
tient care, the physician must be capable of engaging
and educating support systems, such as families,
home health care agencies, and referring providers. Fi-
nally, given the often-abrupt transitions of the goals of
care from that of cure to end-of-life management, a ca-
pable HCT physician will demonstrate excellence in
the communication of serious news.
Learners in an HCT training program should
achieve competence in interpersonal and communica-
tion skills as shown by the following items:
A. Demonstrate effective communication (both verbal
and nonverbal) of medical plans for HCT patients.
B. Effectively engage the patient and family in the
process of informed consent for HCT and clinical
protocols.
C. Effectively communicate HCT-related recom-
mendations, evaluation, and outpatient follow-up
care needs to the patient, family, referring physi-
cian, and other support personnel.
D. Effectively communicate serious news to patients
and families regarding a transition to end-of-life
care.
E. Effectively discuss advanced directives where appli-
cable.
F. Effectively facilitate the flow of relevant informa-
tion to other members of the HCT team, including
nurses, social service workers, therapists, financial
and other HCT coordinators, laboratory workers,
and others.
G. Effectively communicate andcollaboratewithother
HCT physicians and transplantation programs.
IV. Practice-Based Learning and Improvement
According to the ACGME, competency in
practice-based learning and improvement (PBLI) is
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care of patients, to appraise and assimilate scientific ev-
idence, and to continuously improve patient care based
on constant self-evaluation and life-long learning’’ [5].
Included in PBLI is the identification of strengths and
deficiencies in one’s medical knowledge and the ability
to perform appropriate learning activities to improve
the overall quality of care. The learner should be
able to formulate a system to seek relevant feedback
regarding the quality of clinical care and a plan to in-
corporate that feedback into improvement of daily
practice. Competency in PBLI includes demonstrating
proficiency in the ability to locate, appraise, and assim-
ilate scientific evidence related to patient care in aman-
ner that improves clinical outcome. PBLI also includes
competence in the ability to share and teach medical
information. Learners will demonstrate competence
as an educator of patients, families, students, residents,
and other health professionals.
Operation of a successful HCT program requires
participants well skilled in PBLI because of the intrin-
sic nature of the medical practice of HCT, which
demands focused attention to issues of donor and
recipient safety, process control and improvement,
management of standard operating procedures, and
provision of educational services to patients required
to provide informed consent for a complex medical
procedure. In addition, competence in PBLI is man-
dated by regulatory bodies with direct oversight of
HCT programs, including FACT and the FDA, and
is required for participating in the NMDP. A success-
ful HCT programmust have a plan in place for contin-
uous quality improvement that includes the clinical,
and hematopoietic stem cell laboratory programs.
Competent HCT physicians are required to devise
and implement quality improvement programs that in-
clude multidisciplinary teams that collect and report
outcome data, manage databases, perform audits, and
organize improvement efforts. They must be knowl-
edgeable in basic concepts of quality improvement
programs and ‘‘plan, do, study, act’’ cycles of continu-
ous improvement and how these efforts affect outcome
measures that are required to be reported by a US
federal mandate.
Successful HCT requires cooperation and com-
mitment from patients, who must comply with a com-
plex medical treatment plan and be knowledgeable in
the rationale and pitfalls of the treatment plan. Patients
are also required to provide informed consent for
HCT, which requires a working knowledge of the
HCT process, benefits, and risks. This is a daunting
task that requires the HCT physicians and other staff
to serve an educational role. Moreover, the multidisci-
plinary team needed for successful management of
HCT recipients needs practical knowledge of the var-
ious HCT treatment plans, including complications,
risks, and benefits, as well as the rationale for treat-ment, to effectively provide medical care to patients.
A successful HCT physician will by necessity be an ex-
cellent educator of patients, staff, and other faculty
members to facilitate the dissemination of accurate
and timely information and to enable the provision
of up-to-date medical care from all members of the
HCT team. The learners in an HCT training program
should receive training and evaluation of their teaching
skills with respect to their interactions with patients
and members of the HCT team.
Trainees in an HCT training program should
achieve competence in PBLI as demonstrated by the
following items:
A. Demonstrate an ability to devise and implement
a plan for continuous quality improvement that is
applicable for an HCT clinical program, stem cell
laboratory, or apheresis collection programs.
B. Analyze HCT program experience and outcome
and perform practice-based improvement activities
using a systematic methodology (eg, plan-
do-study-act) that meets FACT standards.
C. Locate, appraise, and assimilate evidence from sci-
entific studies related to patients’ health problems
and demonstrate the ability to critically analyze sci-
entific studies.
D. Use information technology to manage patient in-
formation, access on-linemedical information, and
support educational efforts.
E. Demonstrate understanding of clinical epidemiol-
ogy and medical statistics, including clinical study
and experimental protocol design, data collection,
and analysis.
F. Demonstrate the ability to teach patients andmem-
bers of an HCT team.
V. Systems-Based Practice
Of the 6 ACGME core competencies, systems-
based practice is one of the most challenging to de-
fine and incorporate into clinical practice. The focus
is on understanding how parts of a system of health
care are interdependent and identifying changes that
can be both made and measured to improve care
within the system [5]. Transplantation physicians
also need the knowledge and ability to call on other
resources within the system to provide optimal care
of HCT recipients.
Given the high cost of HCT, it is imperative that
trainees receive training in all of the unique financial
aspects, quality control procedures, and program ad-
ministration associated with the procedure, as follows:
A. Recognize financial issues related to HCT, includ-
ing the cost of donor search and acquisition, as well
as the costs associated with the prolonged nature of
HCT therapy and its complications.
B. Understand the impact of contracts with insurance
companies, health maintenance organizations, and
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HCT and patient care.
C. Practice cost-effective health care and resource al-
location that does not compromise quality of care;
advocate for quality patient care and assist patients
in dealing with system complexities.
D. Demonstrate the leadership and management
skills necessary to provide clinical services in an
HCT program, cell therapy laboratory, and apher-
esis collection programs.
E. Understand quality control procedures and pro-
gram administration:
1. Understand the need for and be able to develop
standard operating protocols.
2. Understand the need for and be able to develop
record keeping, error tracking, and personnel de-
velopment methods.
3. Understand the process for and participate in in-
spection proceedings of regulatory agencies, (eg,
FACT, FDA).
4. Understand the need for conducting cost analyses
and for developing and adhering to budgets.
VI. Professionalism
According to the ACGME, the 3 major compo-
nents of professionalism are commitment, adherence,
and sensitivity [5]. Commitment includes respect, in-
tegrity, compassion, empathy, and dependability, as
well as accountability and a professional commitment
to excellence. Adherence means accepting responsibil-
ity for continuity of care and practicing patient-
centered care that encompasses confidentiality and
respect for privacy and autonomy through appropriate
informed consent and shared decision making. Finally,
sensitivity relates to showing sensitivity to cultural,
age, sex, and disability issues for both patients and col-
leagues.
The job of transplantation physician is often stress-
ful given the critical nature of issues that arise on a daily
basis. Transplantation physicians must be mindful of
the need to act in a professional manner when interact-
ing with patients, staff, and colleagues at all times, par-
ticularly during times of stress. Professionalism,
including medical ethics, should be emphasized
throughout the program curriculum.
In the context of becoming a transplantation phy-
sician, a trainee should develop the following skills in-
dicative of a professional in the field:
A. Develop and demonstrate a commitment to carry
out professional responsibilities and adhere to eth-
ical principles at all times:
1. Complete records in a timely manner
2. Provide for continuity of care.
B. Provide patient-centered care at all time points
in the transplantation process in a confidentialmanner that demonstrates sensitivity to cultural
issues.
C. Identify and manage conflicts of interest.
D. Demonstrate respect, empathy, and compassionate
use of medical skills for HCT patients receiving
either active therapy or comfort careEVALUATIONS
All core competencies should be evaluated with
a variety of methods to best determine the trainee’s
progress and ultimate competency. The ACGME rec-
ommends using self-assessment tools, individualized
portfolios, chart reviews, and global and multisource
(including staff, patients, peers, and colleagues) evalu-
ation tools [5]. Evaluation of competency in counsel-
ing patients, obtaining informed consent, and the
performance of procedures requires direct observation
by an experienced HCT physician.CONCLUSION
Wehave providedHCT trainers and educators with
a detailed training curriculum for advanced training in all
aspects of transplantation within the context of the 6
ACGME core competencies in medical knowledge, pa-
tient care, interpersonal and communication skills,
PBLI, systems-based practice, and professionalism.
These training guidelines incorporate advances in
HCT since the guidelines were last revised in 2001 and
provide recommendations for evaluation andmentoring
of trainees. As with any curriculum, these guidelines
should be used as a foundation for training requirements
and be adapted to the particular needs of the trainee and
environment of the individual training program.ACKNOWLEDGMENTS
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